Novel approaches to support therapeutic development in ultra-rare cancers
Food and Drug Administration
Classification and identifiers
- Solicitation number
- FOR-FD-26-004
- Assistance listing (CFDA)
- 93.103
Amount
Amount not published by the funder
Who can apply
Native American tribal governments (Federally recognized), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, Small businesses, Special district governments, Public and State controlled institutions of higher education, Independent school districts, County governments, State governments, Native American tribal organizations (other than Federally recognized tribal governments), For profit organizations other than small businesses, City or township governments, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Public housing authorities/Indian housing authorities…
About this opportunity
The purpose of this program is to support new approaches that can be applied to facilitate therapeutic development in ultra-rare pediatric and adult cancers, including molecularly-defined subsets of more common cancers. Specific areas of interest include, but are not limited to, the following examples: • Development of infrastructure for a coordination network and data repository for patient-level data across institutions and internationally to support drug development and regulatory decision-making for one or more ultra-rare cancers. • Investigations to explore opportunities to develop and validate early clinical endpoints and other novel efficacy endpoints for evaluation of treatments for ultra-rare cancers. • Development and implementation of a collaborative multi-stakeholder effort to ...
Related opportunities
- Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)Food and Drug AdministrationUp to $400K
- Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01 Clinical Trials Required)Food and Drug Administration
- Precision Approaches in Radiation Synthetic Combinations (PAIRS, RP1 Clinical Trial Optional)National Institutes of Health
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)National Institutes of HealthCloses Nov 2026Up to $150K
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)National Institutes of HealthCloses Nov 2026Up to $300K
- Novel Approaches to Advance Precision Aging and Cognitive HealthNational Institutes of Health